Literature DB >> 24187607

Adjusting for unknown bias in non-inferiority clinical trials.

Katherine Odem-Davis1, Thomas R Fleming.   

Abstract

Evaluation of non-inferiority is based on ruling out a threshold for what would constitute unacceptable loss of efficacy of an experimental treatment relative to an active comparator "Standard". This threshold, the "non-inferiority margin", is often based on preservation of a percentage of Standard's effect. To obtain an estimate of this effect to be used in the development of the "non-inferiority margin", data are needed from earlier trials comparing Standard to placebo if the non-inferiority trial does not have a placebo arm. This approach often provides a biased over-estimate of Standard's true effect in the setting of the current non-inferiority study. We describe two commonly used non-inferiority margin methods that adjust for this bias, the two-confidence interval (95-95) and the Synthesis margins. However, the added 'variance inflation' adjustment made by 95-95 margin diminishes with increasing information from historical trial(s), and the Synthesis margin is based on a strong assumption that the relative bias is known. We introduce an alternative "Bias-adjusted" margin addressing vulnerabilities of each by attenuating the estimate and by accounting for uncertainty in the true level of bias. Examples and asymptotic estimates of non-inferiority hypothesis rejection rates in the proportional hazards setting are used to compare methods.

Entities:  

Keywords:  Non-inferiority; active control; bias; constancy; margin

Year:  2013        PMID: 24187607      PMCID: PMC3811957          DOI: 10.1080/19466315.2013.795910

Source DB:  PubMed          Journal:  Stat Biopharm Res        ISSN: 1946-6315            Impact factor:   1.452


  7 in total

1.  Choosing an equivalence limit for noninferiority or equivalence studies.

Authors:  Brian L Wiens
Journal:  Control Clin Trials       Date:  2002-02

2.  Design and analysis of non-inferiority mortality trials in oncology.

Authors:  Mark Rothmann; Ning Li; Gang Chen; George Y H Chi; Robert Temple; Hsiao-Hui Tsou
Journal:  Stat Med       Date:  2003-01-30       Impact factor: 2.373

3.  Some essential considerations in the design and conduct of non-inferiority trials.

Authors:  Thomas R Fleming; Katherine Odem-Davis; Mark D Rothmann; Yuan Li Shen
Journal:  Clin Trials       Date:  2011-08       Impact factor: 2.486

4.  Type I error probabilities based on design-stage strategies with applications to noninferiority trials.

Authors:  Mark Rothmann
Journal:  J Biopharm Stat       Date:  2005       Impact factor: 1.051

5.  Preservation of effect and the regulatory approval of new treatments on the basis of non-inferiority trials.

Authors:  Steven Snapinn; Qi Jiang
Journal:  Stat Med       Date:  2008-02-10       Impact factor: 2.373

6.  Current issues in non-inferiority trials.

Authors:  Thomas R Fleming
Journal:  Stat Med       Date:  2008-02-10       Impact factor: 2.373

7.  Placebo-controlled trials and active-control trials in the evaluation of new treatments. Part 1: ethical and scientific issues.

Authors:  R Temple; S S Ellenberg
Journal:  Ann Intern Med       Date:  2000-09-19       Impact factor: 25.391

  7 in total
  4 in total

1.  Detecting and accounting for violations of the constancy assumption in non-inferiority clinical trials.

Authors:  Joseph S Koopmeiners; Brian P Hobbs
Journal:  Stat Methods Med Res       Date:  2016-09-01       Impact factor: 3.021

2.  A simulation study evaluating bio-creep risk in serial non-inferiority clinical trials for preservation of effect.

Authors:  K Odem-Davis; T R Fleming
Journal:  Stat Biopharm Res       Date:  2015-01-01       Impact factor: 1.452

3.  On robustness of noninferiority clinical trial designs against bias, variability, and nonconstancy.

Authors:  Qing Liu; Yulan Li; Katherine Odem-Davis
Journal:  J Biopharm Stat       Date:  2015       Impact factor: 1.051

4.  A note on the determination of non-inferiority margins with application in oncology clinical trials.

Authors:  Binbing Yu; Harry Yang; Antony Sabin
Journal:  Contemp Clin Trials Commun       Date:  2019-09-23
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.